Monoclonal Antibody Infusion

Monoclonal antibody infusion is a promising treatment for COVID-19, as studies have shown that it can help reduce the risk of hospitalization and worsening COVID-19 symptoms. Monoclonal antibodies are similar to antibodies that are produced naturally in the body to respond to an infection, but are artificially produced in a lab and designed to strongly resist the virus by recognizing the spike protein on its outer shell. In doing so, these antibodies interfere with the virus’ ability to multiply within the body, giving the immune system more time to launch a response to the COVID-19 infection. Tampa General Hospital was the first hospital in Florida to offer monoclonal antibody treatment to COVID-19 patients. It is administered in our Global Emerging Diseases Institute (GEDI) outpatient clinic under an emergency use authorization (EUA).

Who Can Receive Monoclonal Antibody Infusion Treatment?

Monoclonal antibody infusion treatment requires a referral and is specifically only for patients who have received a positive COVID-19 test, are within seven days of symptom onset (10 days for immunocompromised patients) and meet one or more of the following high-risk criteria:

  • Are age 65 or older
  • Are currently receiving immunosuppressive treatment

  • Are diabetic

  • Have chronic kidney disease

  • Have a body mass index (BMI) greater than 35

  • Are age 55 or older and also have one or more of the following conditions: hypertension, coronary artery disease, cardiovascular disease or a type of chronic respiratory disease (like chronic obstructive pulmonary disease)

Children 12 years and older who weigh more than 88 pounds (40 kilograms) may also be eligible for this treatment, if they also meet any of the following criteria:

  • They have a BMI in the 85th percentile or higher.

  • They have an immunosuppressive disease or are undergoing immunosuppressive therapies.

  • They use a medical-related technological device unrelated to COVID-19, like a tracheostomy.

  • They have a high-risk condition, such as sickle cell disease, congenital or acquired heart disease, asthma, chronic kidney disease or diabetes.

How Is Monoclonal Antibody Infusion Treatment Administered?

At TGH, we offer two types of monoclonal antibody infusions:

  • Bamlanivimab/etesevimab

  • Casirivimab/imdevimab

This treatment is mostly commonly given intravenously (through an IV), although some patients may receive it through subcutaneous injections. The infusion itself takes about an hour and then patients must wait in observation for an hour. As long as you are not experiencing any adverse effects, you’ll be able to go home afterwards.

What to Expect

There are certain side effects to be aware of when undergoing this treatment. For example, you may experience bleeding, bruising, soreness, swelling or infection at the infusion site.

Common side effects of bamlanivimab/etesevimab include:

  • Fever

  • Irregular heartbeat

  • Fatigue or weakness

  • Confusion

  • Difficulty breathing

Common side effects of casirivimab/imdevimab include:

  • Nausea or vomiting

  • Pneumonia

  • Hyperglycemia

Effectiveness

In studies, monoclonal antibody infusions have shown to reduce hospitalizations and severe illness in patients with COVID-19. This treatment is especially useful for patients with weakened immune systems whose bodies will have a hard time fighting the virus.

Preparing for your appointment

Please arrive 15 minutes early for your appointment. The outpatient infusion clinic is located on the main campus of Tampa General Hospital in the Global Emerging Diseases Institute (GEDI).

Address: 6 Tampa General Cir, Tampa, FL 33606
Directions: As soon as you come across the bridge to Davis Islands, keep left. As you cross the bridge, continue left to the Harborside Pavilion roundabout and keep right at the roundabout. Take the first left immediately after the roundabout facing the water. Follow signs to the GEDI Infusion Clinic. Parking is available in valet spots at the front of the building or in the adjacent garage.

If you have questions, please email or call 813-844-4715.

 

 

Monoclonal antibody infusion is a promising treatment for COVID-19, as studies have shown that it can help reduce the risk of hospitalization and worsening COVID-19 symptoms. Monoclonal antibodies are similar to antibodies that are produced naturally in the body to respond to an infection, but are artificially produced in a lab and designed to strongly resist the virus by recognizing the spike protein on its outer shell. In doing so, these antibodies interfere with the virus’ ability to multiply within the body, giving the immune system more time to launch a response to the COVID-19 infection. Tampa General Hospital was the first hospital in Florida to offer monoclonal antibody treatment to COVID-19 patients. It is administered in our Global Emerging Diseases Institute (GEDI) outpatient clinic under an emergency use authorization (EUA).

Who Can Receive Monoclonal Antibody Infusion Treatment?

Monoclonal antibody infusion treatment requires a referral and is specifically only for patients who have received a positive COVID-19 test, are within seven days of symptom onset (10 days for immunocompromised patients) and meet one or more of the following high-risk criteria:

  • Are age 65 or older
  • Are currently receiving immunosuppressive treatment

  • Are diabetic

  • Have chronic kidney disease

  • Have a body mass index (BMI) greater than 35

  • Are age 55 or older and also have one or more of the following conditions: hypertension, coronary artery disease, cardiovascular disease or a type of chronic respiratory disease (like chronic obstructive pulmonary disease)

Children 12 years and older who weigh more than 88 pounds (40 kilograms) may also be eligible for this treatment, if they also meet any of the following criteria:

  • They have a BMI in the 85th percentile or higher.

  • They have an immunosuppressive disease or are undergoing immunosuppressive therapies.

  • They use a medical-related technological device unrelated to COVID-19, like a tracheostomy.

  • They have a high-risk condition, such as sickle cell disease, congenital or acquired heart disease, asthma, chronic kidney disease or diabetes.

How Is Monoclonal Antibody Infusion Treatment Administered?

At TGH, we offer two types of monoclonal antibody infusions:

  • Bamlanivimab/etesevimab

  • Casirivimab/imdevimab

This treatment is mostly commonly given intravenously (through an IV), although some patients may receive it through subcutaneous injections. The infusion itself takes about an hour and then patients must wait in observation for an hour. As long as you are not experiencing any adverse effects, you’ll be able to go home afterwards.

What to Expect

There are certain side effects to be aware of when undergoing this treatment. For example, you may experience bleeding, bruising, soreness, swelling or infection at the infusion site.

Common side effects of bamlanivimab/etesevimab include:

  • Fever

  • Irregular heartbeat

  • Fatigue or weakness

  • Confusion

  • Difficulty breathing

Common side effects of casirivimab/imdevimab include:

  • Nausea or vomiting

  • Pneumonia

  • Hyperglycemia

Effectiveness

In studies, monoclonal antibody infusions have shown to reduce hospitalizations and severe illness in patients with COVID-19. This treatment is especially useful for patients with weakened immune systems whose bodies will have a hard time fighting the virus.

Preparing for your appointment

Please arrive 15 minutes early for your appointment. The outpatient infusion clinic is located on the main campus of Tampa General Hospital in the Global Emerging Diseases Institute (GEDI).

Address: 6 Tampa General Cir, Tampa, FL 33606
Directions: As soon as you come across the bridge to Davis Islands, keep left. As you cross the bridge, continue left to the Harborside Pavilion roundabout and keep right at the roundabout. Take the first left immediately after the roundabout facing the water. Follow signs to the GEDI Infusion Clinic. Parking is available in valet spots at the front of the building or in the adjacent garage.

If you have questions, please email or call 813-844-4715.